Nature Communications (Feb 2019)
Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine
- Slim Fourati,
- Susan Pereira Ribeiro,
- Filipa Blasco Tavares Pereira Lopes,
- Aarthi Talla,
- Francois Lefebvre,
- Mark Cameron,
- J. Kaewkungwal,
- P. Pitisuttithum,
- S. Nitayaphan,
- S. Rerks-Ngarm,
- Jerome H. Kim,
- Rasmi Thomas,
- Peter B. Gilbert,
- Georgia D. Tomaras,
- Richard A. Koup,
- Nelson L. Michael,
- M. Juliana McElrath,
- Raphael Gottardo,
- Rafick-Pierre Sékaly
Affiliations
- Slim Fourati
- Department of Pathology, Case Western Reserve University
- Susan Pereira Ribeiro
- Department of Pathology, Case Western Reserve University
- Filipa Blasco Tavares Pereira Lopes
- Department of Pathology, Case Western Reserve University
- Aarthi Talla
- Department of Pathology, Case Western Reserve University
- Francois Lefebvre
- Canadian Center for Computational Genomics
- Mark Cameron
- Department of Epidemiology and Biostatistics, Case Western Reserve University
- J. Kaewkungwal
- Faculty of Tropical Medicine, Mahidol University
- P. Pitisuttithum
- Faculty of Tropical Medicine, Mahidol University
- S. Nitayaphan
- Royal Thai Army, Armed Forces Research Institute of Medical Sciences
- S. Rerks-Ngarm
- Department of Disease Control, Ministry of Public Health
- Jerome H. Kim
- Military HIV Research Program, Walter Reed Army Institute of Research
- Rasmi Thomas
- Military HIV Research Program, Walter Reed Army Institute of Research
- Peter B. Gilbert
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
- Georgia D. Tomaras
- Duke Human Vaccine Institute, Duke University
- Richard A. Koup
- Vaccine Research Center, US National Institutes of Health
- Nelson L. Michael
- Military HIV Research Program, Walter Reed Army Institute of Research
- M. Juliana McElrath
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
- Raphael Gottardo
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
- Rafick-Pierre Sékaly
- Department of Pathology, Case Western Reserve University
- DOI
- https://doi.org/10.1038/s41467-019-08854-2
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 12
Abstract
The RV144 vaccine trial showed reduced risk of HIV-1 acquisition, but mechanisms underlying protection are poorly understood. Here, Fourati et al. assess the transcriptomic profile of blood collected from 223 vaccinees and 40 placebo recipients and identify IRF7 as a mediator of protection.
